Table 1.
Case list.
| # | Age | Sex | Follow-up (mo) | Side | Initial arthroplasty | Comorbidity | Causal bacteria | Antibiotics (g/cement 40 g) | Mold use | Waiting period (d) | Two-stage surgery |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 77 | M | 8a | R | Total knee arthroplasty | Renal cell cancer | Staphylococcus epidermidis | AMK (1.6), TEIC (1.6) | Yes | 141 | Revision |
| 2 | 71 | F | 36a | L | Hemiarthroplasty | Bladder cancer, osteomyelitis pubis | Negative | AMK (1.5), VCM (1) | Yes | 106 | Removal |
| 3 | 68 | M | 73 | R | Total knee arthroplasty | Hypertension | Staphylococcus epidermidis | AMK (1), VCM (2), TEIC (1) | Yes | 106 | Revision |
| 4 | 76 | F | 67 | L | Total knee arthroplasty | Hypertension | Negative | AMK (2), TEIC (2) | Yes | 154b | Revision |
| 5 | 80 | M | 54 | R | Total knee arthroplasty | Cholecystitis | MRSA | AMK (2), TEIC (1.1) | No | 184 | Revision |
| 6 | 70 | F | 38 | L | Total hip arthroplasty | Hypertension, hyperuricaemia | Negative | AMK (1.5), VCM (1.5) | Yes | 30 | Revision |
| 7 | 81 | F | 27 | L | Total hip arthroplasty | Hypertension | α-Streptococcus | AMK (1.6), VCM (2) | No | 60b | Removal |
| 8 | 77 | F | 17 | R | Hemiarthroplasty | Hypertension, dyslipidemia | Staphylococcus epidermidis | AMK (2), VCM (1) | No | 38 | Revision |
| 9 | 75 | F | 17 | L | Total elbow arthroplasty | Rheumatoid arthritis | MSSA | AMK (4) | No | 43 | Revision |
| 10 | 66 | M | 13 | L | Total hip arthroplasty | Hepatitis C | Staphylococcus epidermidis | AMK (1.2), VCM (2) | No | 40 | Revision |
| 11 | 57 | M | 8 | L | Total hip arthroplasty | Hyperuricaemia | MRSE | AMK (1.2), VCM (2) | No | 28 | Revision |
AMK, amikacin; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; TEIC, teicoplanin;VCM, vancomycin.
a
Death in progress.
b
Replacement in progress.